Efektivitas Progesteron Oral dan Vagina pada Tata Laksana Abortus Imminens
DOI:
https://doi.org/10.55175/cdk.v50i6.922Kata Kunci:
Abortus imminens, progesteron oral, progesteron vaginalAbstrak
Abortus imminens adalah perdarahan yang terjadi sebelum usia kehamilan 20 minggu, tanpa keluarnya janin. Selama kehamilan, progesteron berperan dalam proses implantasi janin ke dalam rahim. Beberapa penelitian menunjukkan bahwa progesteron bermanfaat dalam penanganan abortus imminens, baik dalam bentuk oral maupun supositoria. Sediaan oral terbukti lebih efektif dibandingkan progesteron vaginal.
Threatened miscarriage or imminent abortion is vaginal bleeding that happened before a 20-week gestation without fetus expulsion. During pregnancy, progesterone plays a role in the process of implanting the fetus into the uterus. Several studies have shown that oral and suppository progesterone are beneficial for imminent abortion treatment, both in oral and suppository form. Oral preparations have proved to be more effective than vaginal progesterone.
Unduhan
Referensi
Alokananda Ray. The role of progesteron in miscarriage. Int J Gynecol Obstet & Neona Care. 2016;3:34–40.
Shah D, Nagarajan N. Luteal insufficiency in first trimester. Indian J Endocr Metab. 2013;17(1):44.
Arab H, Alharbi A Jaber, Oraif A, Sagr E, Al Madani H, Abduljabbar H, et al. The role of progestogens in threatened and idiopathic recurrent miscarriage. IJWH. 2019 Nov;Volume 11:589–96.
Lee HJ, Park TC, Kim JH, Norwitz E, Lee B. The influence of oral dydrogesterone and vaginal progesterone on threatened abortion: A systematic review and meta-analysis. BioMed Res Internati. 2017;2017:1–10.
Ku CW, Tan ZW, Lim MK, Tam ZY, Lin CH, Ng SP, et al. Spontaneous miscarriage in first trimester pregnancy is associated with altered urinary metabolite profile. BBA Clinical. 2017;8:48–55.
Qing G, Hong Y, Feng X. Comparison of oral dydrogesterone and intramuscular progesterone in the treatment of threatened abortion. Biomedica. 2015;31(3):223–227.
Salda Abrar, Tahira Abrar, Muhammad Tahir, Ehsan Sayyed. Role of progesterone in the treatment of threatened miscarriage in first trimester. BMC Pregnancy Childbirth. 2017;4:407–10.
Yassaee F, Shekarriz-Foumani R, Afsari S, Fallahian M. The effect of progesterone suppositories on threatened abortion: a randomized clinical trial. J Reproduction Infertility. 2014;15(3):147–51.
Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol. 2012;28(12):983–90.
FOGSI. FOGSI position statement on the use of progestogens. 2015.
Kaur KK. Luteal phase support using oral dydrogesterone-a prospective treatment for future replacing micronized vaginal progesterone. OAJRSD. 2018;1(4).
Wang X, Luo Q, Bai W. Efficacy of progesterone on threatened miscarriage: Difference in drug types. J Obstet Gynaecol Res. 2019;45(4):794–802.
Czajkowski K, Sienko J, Mogilinski M, Bros M, Szczecina R, Czajkowska A. Uteroplacental circulation in early pregnancy complicated by threatened abortion supplemented with vaginal micronized progesterone or oral dydrogesterone. Fertil Steril. 2007;87(3):613–8.
Coomarasamy A, Devall AJ, Brosens JJ, Quenby S, Stephenson MD, Sierra S, et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am J Obstetr Gynecol. 2020;223(2):167–76.
Palagiano A, Bulletti C, Pace MC, De Ziegler D, Cicinelli E, Izzo A. Effects of vaginal progesterone on pain and uterine contractility in patients with threatened abortion before twelve weeks of pregnancy. Ann NY Acad Sci. 2004;1034(1):200–10.
Li L, Zhang Y, Tan H, Bai Y, Fang F, Faramand A, et al. Effect of progestogen for women with threatened miscarriage: A systematic review and metaanalysis. BJOG. 2020;127(9):1055–63.
Parveen R, Khakwani M, Tabassum S, Masood S. Oral versus vaginal micronized progesterone for the treatment of threatened miscarriage. Pak J Med Sci. 2021;37(3).
Unduhan
Diterbitkan
Cara Mengutip
Terbitan
Bagian
Lisensi
Hak Cipta (c) 2023 Cermin Dunia Kedokteran
Artikel ini berlisensi Creative Commons Attribution-NonCommercial 4.0 International License.
